Literature DB >> 32622444

Central Obesity is Associated With Neuropathy in the Severely Obese.

Brian C Callaghan1, Evan Reynolds2, Mousumi Banerjee2, Ericka Chant2, Emily Villegas-Umana2, Eva L Feldman2.   

Abstract

OBJECTIVE: To determine the prevalence of neuropathy stratified by glycemic status and the association between extensive anthropometric measurements and neuropathy. PATIENTS AND METHODS: We performed a cross-sectional, observational study in obese individuals, before surgery, with body mass index (BMI) greater than 35 kg/m2. Lean controls were recruited from a research website. Neuropathy was defined by the Toronto consensus definition of probable neuropathy. We compared nine anthropometric measurements between obese participants with and without neuropathy. We used multivariable logistic regression to explore associations between these measures, and other metabolic risk factors, and neuropathy.
RESULTS: We recruited 138 obese individuals and 46 lean controls. The mean age (SD) was 45.1 (11.3) years in the obese population (76.1% female, n=105) and 43.8 (12.1) years in the lean controls (82.2% female, n=37). The prevalence of neuropathy was 2.2% (n=1) in lean controls, 12.1% (n=4) in obese participants with normoglycemia, 7.1% (n=4) in obese participants with pre-diabetes, and 40.8% (n=20) in obese participants with diabetes (p≤.01). Waist circumference was the only anthropometric measure that was larger in those with neuropathy (139.3 cm vs 129.1 cm, p=.01). Hip-thigh (71.1 cm vs 76.6 cm, p<.01) and mid-thigh (62.2 cm vs 66.3 cm, p=.03) circumferences were smaller in those with neuropathy. The body mass index was comparable between patients who were obese with and without neuropathy (p=.86). Waist circumference (odds ratio [OR], 1.39; 95% CI, 1.10 to 1.75), systolic blood pressure (OR, 2.89; 95% CI, 1.49 to 5.61), and triglycerides (OR, 1.31; 95% CI, 1.00 to 1.70) were significantly associated with neuropathy.
CONCLUSION: Normoglycemic obese patients have a high prevalence of neuropathy indicating that obesity alone may be sufficient to cause neuropathy. Waist circumference, but not general obesity, is significantly associated with neuropathy.
Copyright © 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32622444      PMCID: PMC7340115          DOI: 10.1016/j.mayocp.2020.03.025

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  34 in total

1.  Development of a brief measure to assess quality of life in obesity.

Authors:  R L Kolotkin; R D Crosby; K D Kosloski; G R Williams
Journal:  Obes Res       Date:  2001-02

2.  The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population.

Authors:  A J Boulton; G Knight; J Drury; J D Ward
Journal:  Diabetes Care       Date:  1985 Mar-Apr       Impact factor: 19.112

3.  Metabolic Syndrome Components Are Associated With Symptomatic Polyneuropathy Independent of Glycemic Status.

Authors:  Brian C Callaghan; Rong Xia; Mousumi Banerjee; Nathalie de Rekeneire; Tamara B Harris; Anne B Newman; Suzanne Satterfield; Ann V Schwartz; Aaron I Vinik; Eva L Feldman; Elsa S Strotmeyer
Journal:  Diabetes Care       Date:  2016-03-10       Impact factor: 19.112

4.  Vascular risk factors and diabetic neuropathy.

Authors:  Solomon Tesfaye; Nish Chaturvedi; Simon E M Eaton; John D Ward; Christos Manes; Constantin Ionescu-Tirgoviste; Daniel R Witte; John H Fuller
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

5.  The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.

Authors:  P J Dyck; K M Kratz; J L Karnes; W J Litchy; R Klein; J M Pach; D M Wilson; P C O'Brien; L J Melton; F J Service
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

6.  The Inventory for Depressive Symptomatology (IDS): preliminary findings.

Authors:  A J Rush; D E Giles; M A Schlesser; C L Fulton; J Weissenburger; C Burns
Journal:  Psychiatry Res       Date:  1986-05       Impact factor: 3.222

7.  Metabolic syndrome is related to polyneuropathy and impaired peripheral nerve function: a prospective population-based cohort study.

Authors:  Rens Hanewinckel; Judith Drenthen; Symen Ligthart; Abbas Dehghan; Oscar H Franco; Albert Hofman; M Arfan Ikram; Pieter A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-09-21       Impact factor: 10.154

8.  Peripheral neuropathy is associated with insulin resistance independent of metabolic syndrome.

Authors:  Ling Han; Lijin Ji; Jing Chang; Jian Wen; Wenting Zhao; Hongli Shi; Linuo Zhou; Yiming Li; Renming Hu; Ji Hu; Bin Lu
Journal:  Diabetol Metab Syndr       Date:  2015-03-03       Impact factor: 3.320

9.  Diabetes and obesity are the main metabolic drivers of peripheral neuropathy.

Authors:  Brian C Callaghan; LeiLi Gao; Yufeng Li; Xianghai Zhou; Evan Reynolds; Mousumi Banerjee; Rodica Pop-Busui; Eva L Feldman; Linong Ji
Journal:  Ann Clin Transl Neurol       Date:  2018-02-14       Impact factor: 4.511

10.  Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors:  Marie Ng; Tom Fleming; Margaret Robinson; Blake Thomson; Nicholas Graetz; Christopher Margono; Erin C Mullany; Stan Biryukov; Cristiana Abbafati; Semaw Ferede Abera; Jerry P Abraham; Niveen M E Abu-Rmeileh; Tom Achoki; Fadia S AlBuhairan; Zewdie A Alemu; Rafael Alfonso; Mohammed K Ali; Raghib Ali; Nelson Alvis Guzman; Walid Ammar; Palwasha Anwari; Amitava Banerjee; Simon Barquera; Sanjay Basu; Derrick A Bennett; Zulfiqar Bhutta; Jed Blore; Norberto Cabral; Ismael Campos Nonato; Jung-Chen Chang; Rajiv Chowdhury; Karen J Courville; Michael H Criqui; David K Cundiff; Kaustubh C Dabhadkar; Lalit Dandona; Adrian Davis; Anand Dayama; Samath D Dharmaratne; Eric L Ding; Adnan M Durrani; Alireza Esteghamati; Farshad Farzadfar; Derek F J Fay; Valery L Feigin; Abraham Flaxman; Mohammad H Forouzanfar; Atsushi Goto; Mark A Green; Rajeev Gupta; Nima Hafezi-Nejad; Graeme J Hankey; Heather C Harewood; Rasmus Havmoeller; Simon Hay; Lucia Hernandez; Abdullatif Husseini; Bulat T Idrisov; Nayu Ikeda; Farhad Islami; Eiman Jahangir; Simerjot K Jassal; Sun Ha Jee; Mona Jeffreys; Jost B Jonas; Edmond K Kabagambe; Shams Eldin Ali Hassan Khalifa; Andre Pascal Kengne; Yousef Saleh Khader; Young-Ho Khang; Daniel Kim; Ruth W Kimokoti; Jonas M Kinge; Yoshihiro Kokubo; Soewarta Kosen; Gene Kwan; Taavi Lai; Mall Leinsalu; Yichong Li; Xiaofeng Liang; Shiwei Liu; Giancarlo Logroscino; Paulo A Lotufo; Yuan Lu; Jixiang Ma; Nana Kwaku Mainoo; George A Mensah; Tony R Merriman; Ali H Mokdad; Joanna Moschandreas; Mohsen Naghavi; Aliya Naheed; Devina Nand; K M Venkat Narayan; Erica Leigh Nelson; Marian L Neuhouser; Muhammad Imran Nisar; Takayoshi Ohkubo; Samuel O Oti; Andrea Pedroza; Dorairaj Prabhakaran; Nobhojit Roy; Uchechukwu Sampson; Hyeyoung Seo; Sadaf G Sepanlou; Kenji Shibuya; Rahman Shiri; Ivy Shiue; Gitanjali M Singh; Jasvinder A Singh; Vegard Skirbekk; Nicolas J C Stapelberg; Lela Sturua; Bryan L Sykes; Martin Tobias; Bach X Tran; Leonardo Trasande; Hideaki Toyoshima; Steven van de Vijver; Tommi J Vasankari; J Lennert Veerman; Gustavo Velasquez-Melendez; Vasiliy Victorovich Vlassov; Stein Emil Vollset; Theo Vos; Claire Wang; XiaoRong Wang; Elisabete Weiderpass; Andrea Werdecker; Jonathan L Wright; Y Claire Yang; Hiroshi Yatsuya; Jihyun Yoon; Seok-Jun Yoon; Yong Zhao; Maigeng Zhou; Shankuan Zhu; Alan D Lopez; Christopher J L Murray; Emmanuela Gakidou
Journal:  Lancet       Date:  2014-05-29       Impact factor: 79.321

View more
  16 in total

Review 1.  Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review.

Authors:  Hannah C Timmins; David Mizrahi; Tiffany Li; Matthew C Kiernan; David Goldstein; Susanna B Park
Journal:  J Cancer Surviv       Date:  2021-01-12       Impact factor: 4.442

2.  Dietary weight loss in people with severe obesity stabilizes neuropathy and improves symptomatology.

Authors:  Brian C Callaghan; Evan L Reynolds; Mousumi Banerjee; Gulcin Akinci; Ericka Chant; Emily Villegas-Umana; Amy E Rothberg; Charles F Burant; Eva L Feldman
Journal:  Obesity (Silver Spring)       Date:  2021-11-07       Impact factor: 5.002

Review 3.  A Role for Fatty Acids in Peripheral Neuropathy Associated with Type 2 Diabetes and Prediabetes.

Authors:  Amy E Rumora; Bhumsoo Kim; Eva L Feldman
Journal:  Antioxid Redox Signal       Date:  2022-04-26       Impact factor: 7.468

Review 4.  Obesity-Associated Neuropathy: Recent Preclinical Studies and Proposed Mechanisms.

Authors:  Raiza Bonomo; Sarah Kramer; Virginie M Aubert
Journal:  Antioxid Redox Signal       Date:  2022-05-23       Impact factor: 7.468

5.  Systems Biology to Address Unmet Medical Needs in Neurological Disorders.

Authors:  Masha G Savelieff; Mohamed H Noureldein; Eva L Feldman
Journal:  Methods Mol Biol       Date:  2022

6.  The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors.

Authors:  Hannah C Timmins; Tiffany Li; David Goldstein; Terry Trinh; David Mizrahi; Michelle Harrison; Lisa G Horvath; Michael Friedlander; Matthew C Kiernan; Susanna B Park
Journal:  J Cancer Surviv       Date:  2021-02-27       Impact factor: 4.442

7.  Altered plasma serine and 1-deoxydihydroceramide profiles are associated with diabetic neuropathy in type 2 diabetes and obesity.

Authors:  V Fridman; S Zarini; S Sillau; K Harrison; B C Bergman; E L Feldman; J E B Reusch; B C Callaghan
Journal:  J Diabetes Complications       Date:  2021-01-09       Impact factor: 2.852

8.  Plasma Metabolomics and Lipidomics Differentiate Obese Individuals by Peripheral Neuropathy Status.

Authors:  Kai Guo; Masha G Savelieff; Amy E Rumora; Fadhl M Alakwaa; Brian C Callaghan; Junguk Hur; Eva L Feldman
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

9.  Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.

Authors:  David Mizrahi; Susanna B Park; Tiffany Li; Hannah C Timmins; Terry Trinh; Kimberley Au; Eva Battaglini; David Wyld; Robert D Henderson; Peter Grimison; Helen Ke; Peter Geelan-Small; Julie Marker; Brian Wall; David Goldstein
Journal:  JAMA Netw Open       Date:  2021-02-01

10.  The determinants of complication trajectories in American Indians with type 2 diabetes.

Authors:  Evan L Reynolds; Gulcin Akinci; Mousumi Banerjee; Helen C Looker; Adam Patterson; Robert G Nelson; Eva L Feldman; Brian C Callaghan
Journal:  JCI Insight       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.